BlueCrest Capital Management’s Haemonetics HAE Stock Holding History

BlueCrest Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,600	Closed	-$298K	–	253
2023 Q1	$298K	Buy	+3,600	New	+$291K	0.01%	217
2019 Q2	–	Sell	-6,560	Closed	-$574K	–	697
2019 Q1	$574K	Buy	+6,560	New	+$597K	0.02%	429
2018 Q4	–	Sell	-3,429	Closed	-$393K	–	1091
2018 Q3	$393K	Buy	+3,429	New	+$355K	0.01%	889
2018 Q2	–	Sell	-3,438	Closed	-$252K	–	1623
2018 Q1	$252K	Buy	+3,438	New	+$236K	0.01%	1163

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlueCrest Capital Management's HAE Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Haemonetics (HAE) in Q2 2023, closing a stake of 3,600 shares — an estimated $298K sold.

BlueCrest Capital Management first reported a position in HAE in Q1 2018 and held it in 4 quarters. The position peaked at $574K in Q1 2019. 296 funds tracked by Wall St. Rank hold HAE as of Q2 2023.

BlueCrest Capital Management reported no remaining Haemonetics position as of Q2 2023 after selling out during the quarter.
BlueCrest Capital Management sold 3,600 Haemonetics shares in Q2 2023, an estimated $298K.
BlueCrest Capital Management first reported a position in Haemonetics in Q1 2018 and held it in 4 quarters.
BlueCrest Capital Management's Haemonetics position peaked at $574K in Q1 2019.
296 funds tracked by Wall St. Rank held Haemonetics as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.